Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Mercedes
Mercedes Alonso Cascon, Madrid ES
| Patent application number | Description | Published |
|---|---|---|
| 20080275088 | Use of Collismycin and Derivatives Thereof as Oxidative Stress Inhibitors - The present invention relates to the use of Collismycin and derivatives thereof as inhibitors of oxidative stress in cells and their use for the preparation of medicaments for the treatment and/or prevention of oxidative stress-induced diseases or conditions, especially neurodegenerative diseases, such as Alzheimer's Disease and Parkinson's Disease. | 11-06-2008 |
| 20090124686 | GSK-3 INHIBITORS - The invention relates to urea derivatives of formula (I) as inhibitors of glycogen synthase kinase 3β, GSK-3, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which GSK-3 is involved, such as Alzheimer's disease or non-insulin dependent diabetes mellitus. | 05-14-2009 |
| 20090192204 | N-(2-THIAZOLYL)-AMIDE DERIVATIVES AS GSK-3 INHIBITORS - The present invention relates to the use of N-(2-thiazolyl)-amide derivatives of formula (I) for the treatment and/or prophylaxis of a disease in which glycogen synthase kinase 3 (GSK-3) is involved, especially neurodegenerative diseases, such as Alzheimer's disease, or non-insulin dependent diabetes mellitus. | 07-30-2009 |
| 20090221647 | N-(2-THIAZOLYL)-AMIDE DERIVATIVES AS GSK-3 INHIBITORS - The present invention relates to the use of N-(2-thiazolyl)-amide derivatives of formula (I), for the treatment and/or prophylaxis of a disease in which glycogen synthase kinase 3 (GSK-3) is involved, especially neurodegenerative diseases, such as Alzheimer's disease, or non-insulin dependent diabetes mellitus. | 09-03-2009 |
| 20100048635 | USE OF COLLISMYCIN AND DERIVATIVES THEREOF AS OXIDATIVE STRESS INHIBITORS - The present invention relates to the use of Collismycin and derivatives thereof as inhibitors of oxidative stress in cells and their use for the preparation of medicaments for the treatment and/or prevention of oxidative stress-induced diseases or conditions, especially neurodegenerative diseases, such as Alzheimer's Disease and Parkinson's Disease. | 02-25-2010 |
Mercedes Alonso Cascon, Tres Cantos (madrid) ES
| Patent application number | Description | Published |
|---|---|---|
| 20100240692 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES - The present invention relates to a new family of [1,10]-phenantroline derivatives of formula (I), which are useful for the treatment or profilaxis of a neurodegenerative or haematological disease or condition, their use as a medicament, especially for treating a treatment neurodegenerative or haematological disease or condition, and a pharmaceutical composition comprising the compounds. | 09-23-2010 |
Mercedes Alonso Cascón, Tres Cantos (madrid) ES
| Patent application number | Description | Published |
|---|---|---|
| 20110213000 | N-(2-THIAZOLYL)-AMIDE DERIVATIVES FOR THE TREATMENT OF OBESITY, DIABETES AND CARDIOVASCULAR DISEASES - The invention relates to the use of a compound of formula (I): | 09-01-2011 |
Mercedes Alvarez Domingo, Barcelona ES
| Patent application number | Description | Published |
|---|---|---|
| 20090124647 | Indole Derivatives as Antitumoral Compounds - Antitumoural compounds of general formula (I); wherein Ar is an heterocyclic group of formula (a) and R | 05-14-2009 |
| 20100048596 | Indole Derivatives as Antitumoral Compounds - Antitumoural compounds of general formula (I); wherein Ar is an heterocyclic group of formula (a) and R | 02-25-2010 |
Mercedes Alvarez Domingo, Sant Joan Despi ES
| Patent application number | Description | Published |
|---|---|---|
| 20110060125 | INDOLESULFONYL PROTECTING GROUPS FOR PROTECTION OF GUANIDINO AND AMINO GROUPS - The invention relates to indolesulfonyl halogenides which are useful for the protection of organic compounds comprising at least one guanidino moiety and/or at least one amino group. The invention further relates to a process for their preparation and their use as protecting reagents. The invention also relates to the process for the protecting reaction and to the protected compounds thereof. | 03-10-2011 |
Mercedes Alvaro Rodriguez, Valencia ES
| Patent application number | Description | Published |
|---|---|---|
| 20080203359 | Electroluminescent Hybrid Material Comprising a Microporous or Mesoporous Solid Containing Covalently-Bonded Organic Compounds Which Confer Electroluminescent Properties to Same - The invention relates to an electroluminescent organic-inorganic hybrid material which is characterised in that it comprises: at least one microporous or mesoporous solid having a structure that is selected from among the structures of zeolites, porous oxides, molecular sieves, silicoaluminophosphates and aluminosilicates; and at least one organic compound which confers electroluminescent properties thereto. The invention is also characterised in that the organic compound is a polycyclic aromatic hydrocarbon, at least part of which is joined to the structure of the microporous or mesoporous solid using covalent bonds. The invention also relates to the method of obtaining said material and to the use thereof. | 08-28-2008 |
Mercedes Armand Ugón, Balears ES
| Patent application number | Description | Published |
|---|---|---|
| 20100022769 | NOVEL POLYNITROGENATED SYSTEMS AS ANTI-HIV AGENTS - The present invention describes the synthesis of the compounds of formulae (1), (2) and (3) in which m and n, which may be identical or different, may have the values 0, 2, 3, 4, 5 and 6; Z and Y, which may be identical or different, represent a nitrogenated cyclic system bonded by nitrogen or by one of the ring carbons or an NR | 01-28-2010 |
Mercedes Armand Ugón, Balears ES
| Patent application number | Description | Published |
|---|---|---|
| 20100022769 | NOVEL POLYNITROGENATED SYSTEMS AS ANTI-HIV AGENTS - The present invention describes the synthesis of the compounds of formulae (1), (2) and (3) in which m and n, which may be identical or different, may have the values 0, 2, 3, 4, 5 and 6; Z and Y, which may be identical or different, represent a nitrogenated cyclic system bonded by nitrogen or by one of the ring carbons or an NR | 01-28-2010 |
Mercedes Ballesteros Perdices, Madrid ES
| Patent application number | Description | Published |
|---|---|---|
| 20100151550 | METHOD FOR RECOVERING ENERGY FROM THE ORGANIC FRACTION OF SOLID URBAN WASTE AND ASSOCIATED FACILITY - The invention relates to a method for recovering energy from the organic fraction of urban solid waste comprising the following steps: a) the organic fraction is pre treated with mineral acids, preferably sulfuric acid, during which the fraction is heated by an outer thermal jacket with no steam injection or steam explosion, thereby producing a first slurry containing an insoluble solid susceptible to enzymatic attack by cellulases; b) a step comprising enzymatic hydrolysis using cellulases and simultaneous fermentation, using an ethanologenic microorganism, of the first slurry in order to obtain a second slurry containing diluted ethanol; and c) distillation of the second slurry such as to obtain wet ethanol, a recyclable liquid effluent and a solid. | 06-17-2010 |
Mercedes Crego Calama, Geldrop-Mierlo NL
| Patent application number | Description | Published |
|---|---|---|
| 20100176822 | NANOWIRE SENSOR - An analyte sensing device is disclosed. In one aspect, the device includes at least one sensing module on a substrate. The sensing module has at least one nanowire including a bottom, an intermediate part and a top, the bottom being closer to the substrate than the top. The module has a surrounding electrode surrounding the bottom and at least part of the intermediate part of each nanowire in height direction and being electrically isolated from the nanowire. There is a gap between each nanowire and the corresponding surrounding electrode allowing penetration of an analyte to be detected between the nanowire and the surrounding electrode. A measurement circuitry is electrically connected to each nanowire and the surrounding electrode for detecting a change in an electrical property as a result of the penetration of the analyte into the gap. | 07-15-2010 |
| 20100264333 | Gas Sensing Device - The present invention relates to a gas sensing device comprising a nanoparticle layer ( | 10-21-2010 |
| 20110192720 | MICROFABRICATED LIQUID-JUNCTION REFERENCE ELECTRODE - Micromachined reference electrodes for use in miniaturized electrochemical sensors, and methods for fabricating such reference electrodes and electrochemical sensors, for example, as a part of a microfluidic system, are disclosed. Electrochemical measurements allow for inexpensive detection of a wide variety of (bio-)chemical compounds in solution. The reference electrode is one of the main parts of an electrochemical cell. The reference electrode, from which no current is drawn, has a stable, constant potential. | 08-11-2011 |
| 20110205543 | Gas Sensor, Method for Optically Measuring the Presence of a Gas Using the Gas Sensor, and Gas Sensing System - The present disclosure relates to a gas sensor including a first layer and a second layer superimposed on each other along an interface between the two layers. The first layer includes an array of nanoparticles along the interface, the nanoparticles provided so as to allow, upon illumination with electromagnetic radiation, long range diffractive coupling of surface plasmon resonances resulting in a surface lattice resonance condition. The second layer includes a material that, when exposed to at least one predetermined gas, detectably affects the surface lattice resonance condition. The material of the second layer preferably has a porosity of at least 10%. | 08-25-2011 |
Mercedes Ferreras, Copenhagen DK
| Patent application number | Description | Published |
|---|---|---|
| 20110052639 | ALLERGEN MUTANTS - Novel recombinant allergens with multiple mutations and reduced IgE binding affinity are disclosed. The allergens are mutants of naturally occurring allergens. The overall α-carbon backbone tertiary structure is essentially preserved. Also disclosed is a method for preparing such recombinant allergens as well as uses thereof. | 03-03-2011 |
Mercedes Ferros Presa, Zamudio (vizcaya) ES
| Patent application number | Description | Published |
|---|---|---|
| 20100213748 | HEADREST SYSTEM, SEAT WITH A HEADREST SYSTEM, AND VEHICLE INCLUDING SAME - The invention relates to a headrest system comprising: | 08-26-2010 |
Mercedes Frances Pedraz, San Sebastian (guipuzcoa) ES
| Patent application number | Description | Published |
|---|---|---|
| 20100223662 | PROGRAMMABLE ELECTRONIC ACCESS CONTROL SYSTEM - The invention relates to a programmable electronic access control system including: an updating unit which operates in conjunction with a central control unit and is provided with management software for global control of installation access. Access elements are associated with the entrance/exit routes, and a credential is associated with each system user. In addition, each updating unit includes means for the bi-directional transfer of data in relation to user credentials, and the central control unit. The updating unit transfers only the information concerning a particular user and the installation closure plan to the user credentials, while receiving information stored on the user credential relating to past events associated therewith, which have been transferred to each of the access elements. | 09-02-2010 |
Mercedes Labiano Ros, Zaragoza ES
| Patent application number | Description | Published |
|---|---|---|
| 20080251106 | Process of cleaning a hard surface with zwitterionic copolymer - The present invention relates to a process of cleaning a hard surface with a composition comprising a specific water-soluble or water-dispersible copolymer, said process comprises the steps of applying said composition onto said surface in diluted form and leaving said diluted composition to dry on said surface without rinsing said surface. | 10-16-2008 |
| 20090075858 | PROCESS FOR TREATING INCLINED HARD SURFACE - The present invention relates to a process of treating a hard surface with a composition comprising polyalkoxylate trisiloxane. More specifically, it relates to a process of treating an inclined or vertical hard surface, wherein a composition comprising polyalkoxylate trisiloxane is applied onto said hard surface. | 03-19-2009 |
| 20090084402 | PROCESS FOR TREATING HARD SURFACE - The present invention relates to a process of treating a hard surface with a composition comprising polyalkoxylate trisiloxane. More specifically, it relates to a process of treating an horizontal hard surface, wherein a composition comprising polyalkoxylate trisiloxane is applied onto said hard surface. | 04-02-2009 |
Mercedes Lobera, Bolton, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090163537 | Thienopyridinone Compounds and Methods of Treatment - The invention relates to 5-HT receptor agonists and partial agonists. Novel thienopyridinone compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include Alzheimer's disease, cognition disorders, irritable bowel syndrome, nausea, emesis, vomiting, prokinesia, gastroesophageal reflux disease, nonulcer dyspepsia, depression, anxiety, urinary incontinence, migraine, arrhythmia, atrial fibrillation, ischemic stroke, gastritis, gastric emptying disorders, feeding disorders, gastrointestinal disorders, constipation, erectile dysfunction, and respiratory depression. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included. | 06-25-2009 |
| 20100184749 | BENZOTHIADIAZINE COMPOUNDS AND THEIR USE - Chemokine receptor antagonists, in particular, compounds of Formula (I) that act as antagonists of the chemokine CCR2 receptor, including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leukocyte accumulation are described herein. | 07-22-2010 |
| 20100197723 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME - Disclosed herein are compounds that may be modulators of 5-HT receptors, and methods of making and using same. | 08-05-2010 |
| 20100317649 | S1P Receptor Modulating Compounds and Use Thereof - The present invention relates to compounds that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. In certain embodiments, the compounds of the invention relate to aryl oxoimidazolidinyls. | 12-16-2010 |
| 20110059945 | S1P Receptor Modulating Compounds and Use Thereof - The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions. | 03-10-2011 |
| 20110195953 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS - The invention generally relates to thienopyridinone 5-HT | 08-11-2011 |
| 20110212940 | S1P Receptor Modulating Compounds and Use Thereof - The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions. | 09-01-2011 |
Mercedes Rodrugues Vieytes, Lugo ES
| Patent application number | Description | Published |
|---|---|---|
| 20110065138 | Quantitative Method For Detecting Yessotoxins In Fishery Products On Based On The Activation That The Toxin Produces In Cellular Phosphodiesterases And Therapeutic Use Of This Activation - The present invention relates to a quantitative method for detecting yessotoxins in fishery products based on the activation the toxin produces on cellular phosphodiesterases and the therapeutic use of this activation. The cellular target of yessotoxin (YTX) and its analogs is the activation of phosphodiesterases (PDEs). The PDEs-YTX bond produces a measurable signal. The bond can be quantified by means of an affinity biosensor or by fluorescence. The biosensor detects biomolecular interactions and allows determining the presence of YTX due to its interaction with PDEs. The variations in the degradation rate of the fluorescent derivative anthraniloyl-cAMP are determined by means of plate fluorescence. The rate at which the PDEs degrade this molecule increases in the presence of YTX. YTX inhibits immunological activation of mastocytes in rats and induces a cytotoxic effect in human hepatocarcinoma cells, which implies two therapeutic uses of YTXs as an antiallergic and antitumor compound. | 03-17-2011 |
Mercedes Salvador-Silva, Rochester, NY US
| Patent application number | Description | Published |
|---|---|---|
| 20110077270 | Compositions and Methods for Treating Ocular Inflammation with Lower Risk of Increased Intraocular Pressure - A composition for treating or controlling an ocular disease or condition comprises a dissociated glucocorticoid receptor agonist (“DIGRA”), which disease or condition has an etiology, or results, in inflammation. The composition can optionally include an anti-inflammatory agent, an anti-infective agent, or both. The composition can be formulated for topical application, injection, or implantation in an affected eye to treat or control the ocular inflammatory disease or condition. | 03-31-2011 |
Mercedes Vazquez-Anon, Chesterfield, MO US
| Patent application number | Description | Published |
|---|---|---|
| 20110021461 | COMBINATIONS TO IMPROVE ANIMAL HEALTH AND PERFORMANCE - The present invention provides combinations of dietary supplements and methods of using of these combinations to improve the health and production performance of animals. In particular, the combinations of the invention comprise antioxidants, trace minerals, organic acids, essential amino acids, and mixtures thereof. | 01-27-2011 |
| 20110172269 | ANTIOXIDANT COMBINATIONS FOR USE IN FEED RATIONS TO INCREASE MILK PRODUCTION AND MILK FAT - The present invention provides a combination of antioxidants that effectively stabilize different types of fats utilized in a ruminant diet. When included in a ruminant feed ration or water source, the antioxidant combination typically increases nutrient digestion, such as fiber and protein, improves rumen fermentation, improves microbial growth, improves microbial efficiency, increases milk production and/or milk fat, improves antioxidant status of the ruminant, and attenuates the negative effects of some fats in the ruminant animal. | 07-14-2011 |
Mercedes Vicioso Sanchez, Madrid ES
| Patent application number | Description | Published |
|---|---|---|
| 20100041897 | Process for preparing a crystalline form of candesartan cilexetil - A process for preparing a crystalline form of candesartan cilexetil referred to as Form I, which has a content of Form II lower than 1% (w/w), is described. The process includes a seeding stage with a crystalline product, which mainly includes Form I, and a digestion stage. The invention also relates to the crystalline form, the pharmaceutical compositions containing it and its use for the preparation of a medicament for the treatment of hypertension. Candesartan cilexetil Form I has shown good stability under accelerated stability conditions, when the content of Form II is lower than 1% w/w. | 02-18-2010 |
Mercedes Villarroya Sánchez, Madrid ES
| Patent application number | Description | Published |
|---|---|---|
| 20100305157 | DERIVATIVES OF DICARBOXYLIC AMINO ACIDS AND THEIR APPLICATION IN THE TREATMENT OF NEURODEGENERATIVE DISEASES - Products of a general formula (I) and their use in the manufacture of medicines useful for the treatment of neurodegenerative diseases such as Alzheimer's disease or, in general, any disease or pathology produced by alterations of biological functions that can be treated or therapeutically modified by these products. | 12-02-2010 |
Mercedes Villarroya Sánchez, Madrid ES
| Patent application number | Description | Published |
|---|---|---|
| 20100305157 | DERIVATIVES OF DICARBOXYLIC AMINO ACIDS AND THEIR APPLICATION IN THE TREATMENT OF NEURODEGENERATIVE DISEASES - Products of a general formula (I) and their use in the manufacture of medicines useful for the treatment of neurodegenerative diseases such as Alzheimer's disease or, in general, any disease or pathology produced by alterations of biological functions that can be treated or therapeutically modified by these products. | 12-02-2010 |
Mercedes Zurita Castillo, Madrid ES
| Patent application number | Description | Published |
|---|---|---|
| 20110123497 | GRAFT COMPOSITION FOR NEURAL TISSUE REGENERATION, METHOD OF PRODUCTION AND USES THEREOF - The present invention provides a biocompatible, biodegradable graft composition for regeneration of neural tissue, comprising the following components: a) a gel scaffold formed from an isolated platelet containing fluid and an activating agent comprising calcium chloride, with or without thrombin, b) a nerve growth factor selected from BDNF, NGF, retinoic acid and combinations thereof, and c) a culture of at least 50,000 progenitor stem cells; the method of production and the uses thereof. | 05-26-2011 |